| Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group SF Barrington, NG Mikhaeel, L Kostakoglu, M Meignan, M Hutchings, ... Journal of clinical oncology 32 (27), 3048, 2014 | 1632 | 2014 |
| Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma P Johnson, M Federico, A Kirkwood, A Fosså, L Berkahn, A Carella, ... New England Journal of Medicine 374 (25), 2419-2429, 2016 | 818 | 2016 |
| Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial HM Prince, YH Kim, SM Horwitz, R Dummer, J Scarisbrick, P Quaglino, ... The Lancet 390 (10094), 555-566, 2017 | 556 | 2017 |
| A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study CS Tam, S Opat, S D'Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, ... Blood, The Journal of the American Society of Hematology 136 (18), 2038-2050, 2020 | 365 | 2020 |
| Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL CS Tam, J Trotman, S Opat, JA Burger, G Cull, D Gottlieb, R Harrup, ... Blood, The Journal of the American Society of Hematology 134 (11), 851-859, 2019 | 333 | 2019 |
| Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia MA Dimopoulos, A Tedeschi, J Trotman, R García-Sanz, D Macdonald, ... New England journal of medicine 378 (25), 2399-2410, 2018 | 324 | 2018 |
| Baseline metabolic tumor volume predicts outcome in high–tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies M Meignan, AS Cottereau, A Versari, L Chartier, J Dupuis, S Boussetta, ... Journal of Clinical Oncology 34 (30), 3618-3626, 2016 | 288 | 2016 |
| First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5 … IW Flinn, R Van Der Jagt, B Kahl, P Wood, T Hawkins, D MacDonald, ... Journal of Clinical Oncology 37 (12), 984, 2019 | 241 | 2019 |
| Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial MA Dimopoulos, J Trotman, A Tedeschi, JV Matous, D Macdonald, C Tam, ... The Lancet Oncology 18 (2), 241-250, 2017 | 234 | 2017 |
| Positron emission tomography–computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset … J Trotman, M Fournier, T Lamy, JF Seymour, A Sonet, A Janikova, ... Journal of Clinical Oncology 29 (23), 3194-3200, 2011 | 233 | 2011 |
| Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety W Hiddemann, AM Barbui, MA Canales, PK Cannell, GP Collins, J Dürig, ... Journal of Clinical Oncology, 2395-2404, 2018 | 220 | 2018 |
| Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide … C Thieblemont, H Tilly, M Gomes da Silva, RO Casasnovas, C Fruchart, ... Journal of Clinical Oncology 35 (22), 2473-2481, 2017 | 200 | 2017 |
| PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study SF Barrington, AA Kirkwood, A Franceschetto, MJ Fulham, TH Roberts, ... Blood, The Journal of the American Society of Hematology 127 (12), 1531-1538, 2016 | 185 | 2016 |
| Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies J Trotman, S Luminari, S Boussetta, A Versari, J Dupuis, C Tychyj, ... The Lancet Haematology 1 (1), e17-e27, 2014 | 169 | 2014 |
| High total metabolic tumor volume at baseline predicts survival independent of response to therapy L Vercellino, AS Cottereau, O Casasnovas, H Tilly, P Feugier, L Chartier, ... Blood, The Journal of the American Society of Hematology 135 (16), 1396-1405, 2020 | 134 | 2020 |
| Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial J Trotman, SF Barrington, D Belada, M Meignan, R MacEwan, C Owen, ... The Lancet Oncology 19 (11), 1530-1542, 2018 | 126 | 2018 |
| Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia JJ Castillo, RH Advani, AR Branagan, C Buske, MA Dimopoulos, S D'Sa, ... The Lancet Haematology 7 (11), e827-e837, 2020 | 123 | 2020 |
| Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma OA O’Connor, M Özcan, ED Jacobsen, JM Roncero, J Trotman, J Demeter, ... Journal of Clinical Oncology 37 (8), 613, 2019 | 111 | 2019 |
| TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets DT Yeung, MP Osborn, DL White, S Branford, J Braley, A Herschtal, ... Blood, The Journal of the American Society of Hematology 125 (6), 915-923, 2015 | 105 | 2015 |
| Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA) E Bachy, V Camus, C Thieblemont, D Sibon, RO Casasnovas, L Ysebaert, ... Journal of Clinical Oncology 40 (3), 242-251, 2022 | 104 | 2022 |
Constantine TamVerified email at tpg.com.au
